Clinical

Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.

This new research sheds light on the importance of follow-up meetings for young patients discharged from emergency departments (EDs).

Amid National C. Diff Awareness Month, Christian John Lillis, cofounder and executive director of the Peggy Lillis Foundation for C. Diff Education & Advocacy, explains the foundation's "See C. diff" campaign and what the PLF hopes the public will learn throughout the month.

The findings suggest the presence of CHIP before HCT may have potential to serve as a biomarker for CVD risk after HCT in patients with multiple myeloma.

Mark A. Socinski, MD, discussed how the understanding of lung cancer has evolved over time, as well as how its heterogeneity impacts treatment strategies.

Patrick Forde, MBBCh, discusses ALK rearrangement in NSCLC and highlights ALINA trial results from ESMO 2023.

An expert comparison of recent data on neoadjuvant and perioperative immunotherapy in resectable early-stage NSCLC, including CheckMate 77T, CheckMate-816, and KEYNOTE-671.

This study characterizes the incidence and associated factors of urolithiasis-related emergency department visits that are potentially preventable with appropriate ambulatory care and calculates their cumulative costs.

Durable mechanistic effects and a good safety profile were found in patients who took mitapivat for sickle cell disease (SCD).

Natasha Halasa, MD, MPH, Vanderbilt University Medical Center, discusses the most pressing diarrheal illness challenges and successful strategies physicians can use to reduce this burden in patients.

Compared with infants born at term, infants born preterm following exposure to HIV had no observed increase in acquisition of HIV.

Patrick Forde, MBBCh, shares insights on perioperative immunotherapy in the CheckMate-77T study presented at ESMO 2023.

Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.

An online survey of patients from multiple countries has shed light on their challenges in getting proper care for ovarian cancer.

Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.

This retrospective review compared appendicular lean mass (ALM) and ALM index among patients with Duchenne muscular dystrophy (DMD) or Becker muscular dystrophy (BMD).

Given the likelihood of MDS to progress to acute myeloid leukemia (AML), the authors state, “There are certain settings where ‘AML-like’ therapies are appropriate in MDS, particularly given our evolving understanding of the overlapping biology of these malignancies.”

HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others.

A study suggests that human papillomavirus (HPV) screenings should be updated due to effective HPV vaccines; a new study shows that osimertinib (Tagrisso, AstraZeneca) reduced both the 5-year risk of recurrent cancer and the risk of death in patients with stage 1B to 3A lung cancer; a new smartphone-controlled technology could help those who suffer from migraines.

The results from this 5-year, open-label extension trial affirm the safety of dupilumab in adults with moderate to severe AD.

Pooled phase 3 data presented at North American Society for Pediatric Gastroenterology, Hepatology & Nutrition 2023 support the benefit-risk profile of the ileal bile acid transport inhibitor in treating the rare liver disease.

Therapy strategies in the management of heart failure are discussed.

The role of the primary care physician (PCP) in heart failure management is explored.

Tirzepatide is already approved to treat type 2 diabetes, and is now approved for chronic weight management in adults with obesity or overweight with at least 1 weight-related condition.

Smoking intensity was shown to be associated with larger microvasculature dropout areas in patients with glaucoma, particularly those with more severe disease.